Abrégé

A melatonin composition has a dry granulation including a melatonin powder with a median melatonin particle size of 5 µm to 40 µm, a carboxylic acid powder, and a powder of a hydrogel-forming polymer. The dry granulation is combined with pharmaceutical excipients in a dry orally ingestible pharmaceutical dosage form adapted to absorb water upon ingestion and form a hydrogel including soluble melatonin and soluble carboxylic acid in the hydrogel, the carboxylic acid being in an amount sufficient to impart a pH of 4.4 or less to the hydrogel after ingestion.

Classes IPC  ?

• A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque

Abrégé

A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.

Classes IPC  ?

• A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/70 - Bases pour bande, feuille ou filament

Abrégé

Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as a GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
• A61K 36/76 - Salicaceae (famille du saule), p. ex. peuplier
• A61K 36/84 - Valerianaceae (famille de la valériane), p. ex. valériane

Abrégé

A composition includes a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with gastric fluid. The dosage form includes an active ingredient combination including an amino acid source and a zinc source, an anionic polymer, an effervescent agent, and a pH buffer. The dosage form is effective for releasing the active ingredient combination while buoyant on gastric fluid.

Classes IPC  ?

• A61K 33/30 - ZincSes composés
• A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/46 - Pilules, pastilles ou comprimés effervescents

Abrégé

A composition includes a therapeutically effective pharmaceutical dosage form including a plurality of individual particulates. The individual particulates respectively have: a core including an active ingredient combination of an L-carnitine and a nootropic substance and a release controlling polymer over the core that substantially prevents release of the active ingredients in stomach acid and permits release of the active ingredients in an intestinal pH environment. The composition may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body and/or cognitive impairment.

Classes IPC  ?

• A61K 9/50 - Microcapsules
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 9/16 - AgglomérésGranulésMicrobilles

Abrégé

A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 36/84 - Valerianaceae (famille de la valériane), p. ex. valériane

Produits et services

Dietary supplements; nutritional supplements; pharmaceutical preparations for use in treating sleep disorders; melatonin preparations for pharmaceutical purposes; valerian preparations for pharmaceutical purposes; over-the-counter pharmaceutical preparations for use in treating sleep disorders.